Malignant Peritoneal Mesothelioma Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is GLUT1 Expression a Major Prognostic Factor? A Preliminary Study-Reference-Cited by-同舟云学术

Malignant Peritoneal Mesothelioma Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is GLUT1 Expression a Major Prognostic Factor? A Preliminary Study

Published:2013-06-26 Issue:12 Volume:20 Page:3892-3898
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Hommell-Fontaine J.,Isaac S.,Passot G.,Decullier E.,Traverse-Glehen A.,Cotte E.,You B.,Mohamed F.,Gilly F. N.,Glehen O.,Berger F.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

http://link.springer.com/content/pdf/10.1245/s10434-013-3077-4.pdf

Reference51 articles.

1. Sebbag G, Yan H, Shmookler BM, Chang D, Sugarbaker PH. Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg. 2000;87:1587-93.

2. Yan TD, Welch L, Black D, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol. 2007;18:827-34.

3. Acherman YI, Welch LS, Bromley CM, Sugarbaker PH. Clinical presentation of peritoneal mesothelioma. Tumori. 2003;89:269-73.

4. Baratti D, Kusamura S, Cabras AD, Laterza B, Balestra MR, Deraco M. Lymph node metastases in diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2010;17:45-53.

5. Brigand C, Monneuse O, Mohamed F, Sayag-Beaujard AC, Isaac S, Gilly FN, Glehen O. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol. 2006;13:405-12.

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma;Cells;2023-08-11

2. Targeting Oncometabolites in Peritoneal Cancers: Preclinical Insights and Therapeutic Strategies;Metabolites;2023-04-30

3. Nivolumab for pediatric malignant peritoneal mesothelioma;Pediatric Blood & Cancer;2022-07-19

4. Key factors for successful cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat diffuse malignant peritoneal mesothelioma: results from specialized peritoneal cancer center in China;International Journal of Hyperthermia;2022-04-29

5. Osteopontin, GLUT1 and Ki‐67 expression in malignant peritoneal mesothelioma: prognostic implications;Internal Medicine Journal;2021-06